Boston Trust Walden’s Dorman Products DORM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,300
| Closed | -$203K | – | 389 |
|
|
2025
Q3 | $203K | Buy |
+1,300
| New | +$186K | ﹤0.01% | 389 |
|
|
2022
Q3 | – | Sell |
-2,440
| Closed | -$268K | – | 357 |
|
|
2022
Q2 | $268K | Hold |
2,440
| – | – | ﹤0.01% | 338 |
|
|
2022
Q1 | $232K | Sell |
2,440
-405,884
| -99% | -$39.3M | ﹤0.01% | 373 |
|
|
2021
Q4 | $46.1M | Sell |
408,324
-721
| -0.2% | -$78.3K | 0.37% | 97 |
|
|
2021
Q3 | $38.7M | Buy |
409,045
+3,863
| +1% | +$381K | 0.34% | 103 |
|
|
2021
Q2 | $42M | Buy |
405,182
+1,313
| +0.3% | +$135K | 0.37% | 97 |
|
|
2021
Q1 | $41.5M | Sell |
403,869
-27,643
| -6% | -$2.76M | 0.4% | 84 |
|
|
2020
Q4 | $37.5M | Buy |
431,512
+65,296
| +18% | +$6.05M | 0.4% | 79 |
|
|
2020
Q3 | $33.1M | Buy |
366,216
+11,892
| +3% | +$950K | 0.41% | 73 |
|
|
2020
Q2 | $23.8M | Buy |
354,324
+16,559
| +5% | +$1.07M | 0.32% | 99 |
|
|
2020
Q1 | $18.7M | Buy |
337,765
+5,730
| +2% | +$390K | 0.3% | 108 |
|
|
2019
Q4 | $25.1M | Buy |
332,035
+9,084
| +3% | +$687K | 0.29% | 104 |
|
|
2019
Q3 | $25.7M | Buy |
322,951
+17,853
| +6% | +$1.39M | 0.32% | 92 |
|
|
2019
Q2 | $26.6M | Sell |
305,098
-2,542
| -0.8% | -$221K | 0.35% | 87 |
|
|
2019
Q1 | $27.1M | Sell |
307,640
-43,328
| -12% | -$3.77M | 0.37% | 82 |
|
|
2018
Q4 | $31.6M | Sell |
350,968
-6,012
| -2% | -$480K | 0.5% | 60 |
|
|
2018
Q3 | $27.5M | Sell |
356,980
-10,006
| -3% | -$765K | 0.38% | 79 |
|
|
2018
Q2 | $25.1M | Buy |
366,986
+3,020
| +0.8% | +$204K | 0.37% | 87 |
|
|
2018
Q1 | $24.1M | Sell |
363,966
-12,635
| -3% | -$900K | 0.37% | 83 |
|
|
2017
Q4 | $23M | Sell |
376,601
-11,602
| -3% | -$787K | 0.34% | 95 |
|
|
2017
Q3 | $27.8M | Sell |
388,203
-4,186
| -1% | -$301K | 0.43% | 70 |
|
|
2017
Q2 | $32.5M | Sell |
392,389
-86,576
| -18% | -$7.07M | 0.52% | 60 |
|
|
2017
Q1 | $39.3M | Sell |
478,965
-43,633
| -8% | -$3.24M | 0.61% | 48 |
|
|
2016
Q4 | $38.2M | Sell |
522,598
-12,416
| -2% | -$848K | 0.6% | 47 |
|
|
2016
Q3 | $34.2M | Sell |
535,014
-3,132
| -0.6% | -$193K | 0.56% | 53 |
|
|
2016
Q2 | $30.8M | Sell |
538,146
-5,307
| -1% | -$285K | 0.53% | 65 |
|
|
2016
Q1 | $29.6M | Sell |
543,453
-6,143
| -1% | -$292K | 0.51% | 62 |
|
|
2015
Q4 | $26.1M | Sell |
549,596
-169,794
| -24% | -$8.28M | 0.48% | 64 |
|
|
2015
Q3 | $36.6M | Sell |
719,390
-23,879
| -3% | -$1.2M | 0.61% | 52 |
|
|
2015
Q2 | $35.4M | Sell |
743,269
-8,155
| -1% | -$397K | 0.54% | 67 |
|
|
2015
Q1 | $37.4M | Sell |
751,424
-11,597
| -2% | -$546K | 0.55% | 66 |
|
|
2014
Q4 | $36.8M | Sell |
763,021
-35,389
| -4% | -$1.64M | 0.55% | 69 |
|
|
2014
Q3 | $32M | Sell |
798,410
-27,348
| -3% | -$1.22M | 0.49% | 80 |
|
|
2014
Q2 | $40.7M | Sell |
825,758
-12,521
| -1% | -$683K | 0.59% | 64 |
|
|
2014
Q1 | $49.5M | Sell |
838,279
-16,895
| -2% | -$927K | 0.74% | 41 |
|
|
2013
Q4 | $47.9M | Buy |
855,174
+59,345
| +7% | +$2.98M | 0.7% | 50 |
|
|
2013
Q3 | $39.4M | Buy |
795,829
+12,637
| +2% | +$619K | 0.6% | 65 |
|
|
2013
Q2 | $35.7M | Buy |
+783,192
| New | +$32.6M | 0.58% | 69 |
|
Other funds holding DORM
GKIM
Boston Trust Walden's DORM Position: Q4 2025 in Review
Boston Trust Walden sold out of Dorman Products (DORM) in Q4 2025, closing a stake of 1,300 shares — an estimated $203K sold.
Boston Trust Walden first reported a position in DORM in Q2 2013 and held it in 38 quarters. The position peaked at $49.5M in Q1 2014. 347 funds tracked by Wall St. Rank hold DORM as of Q4 2025.
- Boston Trust Walden reported no remaining Dorman Products position as of Q4 2025 after selling out during the quarter.
- Boston Trust Walden sold 1,300 Dorman Products shares in Q4 2025, an estimated $203K.
- Boston Trust Walden first reported a position in Dorman Products in Q2 2013 and held it in 38 quarters.
- Boston Trust Walden's Dorman Products position peaked at $49.5M in Q1 2014.
- 347 funds tracked by Wall St. Rank held Dorman Products as of Q4 2025.
Based on Boston Trust Walden's 13F filing for Q4 2025, filed 28 Jan 2026.